(secondQuint)Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants.

 This study is a randomized, blind, single-center, controlled phase III clinical trial.

 The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co.

, Ltd.

 The control vaccine is a commercialized live attenuated mumps vaccine manufactured by Zhejiang VACN bio-pharmaceutical Co.

 Ltd.

 All participants are healthy infants between 8 - 18 months old, and will be randomly assigned into experimental group or control group in the ratio 1:1.

.

 Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants@highlight

The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.

